April 23, 2020 / 10:07 AM / a month ago

BRIEF-Brensocatib To Be Studied In Patients With Severe COVID-19 In Investigator-Initiated Trial

April 23 (Reuters) - Insmed Inc:

* BRENSOCATIB (FORMERLY INS1007) TO BE STUDIED IN PATIENTS WITH SEVERE COVID-19 IN INVESTIGATOR-INITIATED TRIAL

* INSMED INC - INSMED TO SUPPORT STOP-COVID19 STUDY, EXPECTED TO BEGIN IN UK IN MAY 2020

* INSMED INC - STOP-COVID19 TRIAL IS A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF BRENSOCATIB IN PATIENTS WITH SEVERE COVID-19

* INSMED INC - WILL CONTINUE TO DEVELOP BRENSOCATIB IN PATIENTS WITH BRONCHIECTASIS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below